AidaBREAST Assay Validates Spatial Proteomics for Breast Cancer Treatment Decisions
Event summary
- AidaBREAST™, a multi-omic assay developed by PreludeDx on Quanterix's Akoya PhenoImager® HT platform, predicts locoregional recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
- The assay was validated in a study of 922 patients across four academic and clinical centers in the U.S. and Sweden, with a median follow-up of ~10 years.
- AidaBREAST combines spatial multiplex protein expression with targeted next-generation RNA sequencing, leveraging AI for comprehensive tumor biology assessment.
- Quanterix acquired Akoya Biosciences in 2025, adding multiplexed tissue imaging capabilities to its portfolio.
The big picture
The validation of AidaBREAST represents a significant milestone in the clinical application of spatial proteomics, offering a novel tool for personalized treatment decisions in breast cancer. Quanterix's acquisition of Akoya Biosciences positions it as a leader in integrating spatial biology with AI-driven diagnostics, potentially reshaping the oncology diagnostics market. The assay's ability to predict both recurrence risk and therapy benefit underscores the growing importance of multi-omic approaches in precision medicine.
What we're watching
- Clinical Adoption
- How quickly oncologists integrate AidaBREAST into treatment decision-making for early-stage breast cancer patients.
- Market Expansion
- Whether Quanterix can leverage this success to expand spatial proteomics into other cancer types or therapeutic areas.
- Regulatory Pathway
- The pace at which AidaBREAST secures regulatory approvals, enabling broader commercialization.
Related topics